2024

Benefits of aHSCT over alemtuzumab in patients with multiple sclerosis besides disability and relapses: Sustained improvement in cognition and quality of life
Braun B, Fischbach F, Richter J, Pfeffer L, Fay H, Reinhardt S, Friese M, Stellmann J, Kröger N, Heesen C, Häußler V
MULT SCLER RELAT DIS. 2024;82:105414.

Early Neuroaxonal Damage in Neurologic Disorders Associated With GAD65 Antibodies
Eisenhut K, Faber J, Engels D, Gerhards R, Lewerenz J, Doppler K, Sommer C, Markewitz R, Falk K, Rössling R, Pruess H, Finke C, Wickel J, Geis C, Ratuszny D, Pfeffer L, Bittner S, Piepgras J, Kraft A, Klausewitz J, Nuscher B, Kümpfel T, Thaler F
NEUROL-NEUROIMMUNOL. 2024;11(1):.

CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis
Fischbach F, Richter J, Pfeffer L, Fehse B, Berger S, Reinhardt S, Kuhle J, Badbaran A, Rathje K, Gagelmann N, Borie D, Seibel J, Ayuk F, Friese M, Heesen C, Kröger N
MED-CAMBRIDGE. 2024 [Epub ahead of print].

2020

Oligodendrocyte myelin glycoprotein as a novel target for pathogenic autoimmunity in the CNS
Gerhards R, Pfeffer L, Lorenz J, Starost L, Nowack L, Thaler F, Schlüter M, Rübsamen H, Macrini C, Winklmeier S, Mader S, Bronge M, Grönlund H, Feederle R, Hsia H, Lichtenthaler S, Merl-Pham J, Hauck S, Kuhlmann T, Bauer I, Beltran E, Gerdes L, Mezydlo A, Bar-Or A, Banwell B, Khademi M, Olsson T, Hohlfeld R, Lassmann H, Kümpfel T, Kawakami N, Meinl E
ACTA NEUROPATHOL COM. 2020;8(1):207.

Letzte Aktualisierung aus dem FIS: 25.04.2024 - 00:37 Uhr